Clinical Trial Update: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC [Phase 3]

View source ↗

Summary

This document describes an ongoing Phase 3 trial evaluating THIO plus cemiplimab versus chemotherapy as third-line treatment for advanced/metastatic non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• THIO

Snippet

Sponsor: Maia Biotechnology | Conditions: Carcinoma, Non-Small -Cell Lung | Phase 3 | Status: RECRUITING